Compact high power mid-infrared optical parametric oscillator pumped by a gain-switched fiber laser with "figure-of-h" pulse shape.

We demonstrate a compact high power mid-infrared (MIR) optical parametric oscillator (OPO) pumped by a gain-switched linearly polarized, pulsed fiber laser. The gain-switched fiber laser was constructed with a piece of Yb doped polarization maintaining (PM) fiber, a pair of fiber Bragg gratings written into the matched passive PM fiber and 6 pigtailed pump laser diodes working at 915 nm with 30 W output peak power each. By modulating the pulse width of the pump laser diode, simple pedestal-free pulse shape or pedestal-free trailing pulse shape ("figure-of-h" as we call it) could be achieved from the gain-switched fiber laser. The laser was employed as the pump of a two-channel, periodically poled magnesium oxide lithium niobate-based OPO system. High power MIR emission was generated with average output power of 5.15 W at 3.8 µm channel and 8.54 W at 3.3 µm channel under the highest pump power of 45 W. The corresponding pump-to-idler conversion efficiency was computed to be 11.7% and 19.1%, respectively. Experimental results verify a significant improvement to signal-to-idler conversion efficiency by using "figure-of-h" pulses over simple pedestal-free pulses. Compared to the master oscillator power amplifier (MOPA) fiber laser counterpart, the presented gain switched fiber laser is more attractive in OPO pumping due to its compactness and simplicity which are beneficial to construction of OPO systems for practical MIR applications.

High-power PPMgLN-based optical parametric oscillator pumped by a linearly polarized, semi-fiber-coupled acousto-optic Q-switched fiber master oscillator power amplifier.

We have experimentally demonstrated a periodically poled magnesium-oxide-doped lithium niobate (PPMgLN)-based, fiber-laser-pumped optical parametric oscillator (OPO) generating idler wavelength of 3.82 µm. The pump fiber laser was constructed with a linearly polarized, semi-fiber-coupled acousto-optic Q-switched fiber oscillator and a polarization-maintaining fiber amplifier with pulse duration of 190 ns at the highest output power. The OPO was specifically configured in single-pass, singly resonant linear cavity structure to avoid the damage risk of the pump fiber laser, which is always a serious issue in the fiber-laser-pumped, double-pass, singly oscillating structured OPOs. Under the highest pump power of 25 W, an idler average output power of 3.27 W with one-hour peak-to-peak instability of 5.2% was obtained. The measured M2 factors were 1.98 and 1.44 for horizontal and vertical axis, respectively. The high power stability and good beam quality demonstrated the suitability of such technology for practical application.

Fiber laser pumped high power mid-infrared laser with picosecond pulse bunch output.

We report a novel quasi-synchronously pumped PPMgLN-based high power mid-infrared (MIR) laser with picosecond pulse bunch output. The pump laser is a linearly polarized MOPA structured all fiberized Yb fiber laser with picosecond pulse bunch output. The output from a mode-locked seed fiber laser was directed to pass through a FBG reflector via a circulator to narrow the pulse duration from 800 ps to less than 50 ps and the spectral FWHM from 9 nm to 0.15 nm. The narrowed pulses were further directed to pass through a novel pulse multiplier through which each pulse was made to become a pulse bunch composing of 13 sub-pulses with pulse to pulse time interval of 1.26 ns. The pulses were then amplified via two stage Yb fiber amplifiers to obtain a linearly polarized high average power output up to 85 W, which were then directed to pass through an isolator and to pump a PPMgLN-based optical parametric oscillator via quasi-synchronization pump scheme for ps pulse bunch MIR output. High MIR output with average power up to 4 W was obtained at 3.45 micron showing the feasibility of such pump scheme for ps pulse bunch MIR output.

[Determination of thyroid hormones in milk by high performance liquid chromatography-tandem mass spectrometry].

A method of high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) was developed for the determination of thyroid hormones in milk including 3,3',5,5 '-tetraiodothyronine (T4), 3,3', 5-triiodothyronine (T3) and 3,3',5 '-triiodothyronine (rT3). The sample was extracted with acetonitrile and centrifuged, then the up layer was alkalized with concentrated ammonia water and cleaned up with a Cleanert PAX cartridge. The chromatographic separation was carried out on a Zorbax Eclipse XDB-C18 column (150 mm x 2.1 mm, 3.5 micro m) with the mobile phase of 37% water containing 0.1% (v/v) acetic acid and 63% of methanol with an isocratic elution mode at a flow rate of 0. 3 mL/min. The mass spectrometry detection was performed in positive electrospray ionization and monitored using multiple reaction monitoring (MRM) mode (m/z 652. 0/605. 5 and 652. 0/478. 6 for T3 and rT3; m/z 777. 7/731.7 and 777. 7/604.9 for T4; m/z 784. 0/737.9 and 784. 0/639.4 for T4-13C6). The analytes were identified by their retention times and relative abundance ratios of the characteristic product ions, and quantified by internal standard method. The method was linear with the correlation coefficients ( r2 ) greater than 0. 998 in the concentration ranges investigated. The limits of detection (LODs) were not more than 0.03 ng/g, and the limits of quantification (LOQ) were not more than 0.1 ng/g for the analytes. The recoveries were 80. 61% - 101.7% with the relative standard deviations (RSDs) of 1.48% - 9.70%. The results of five real milk samples showed that the contents of T3 were 0.59 - 1. 30 ng/g with the RSDs of 2.06% -7.70%, and T4 and rT3 weren't found. The method presents many merits including simple sample pretreatment, high sensitivity, good reproducibility and unequivocal confirmation and quantification for the analytes. It could be used to monitor the levels of thyroid hormones in the milk for safety quality evaluation.

Compact dual-wavelength Nd:GdVO4 laser working at 1063 and 1065 nm.

We report a compact diode-laser pumped Nd:GdVO(4) laser with stable dual-wavelength output at 1063 nm and 1065 nm simultaneously. Two types of resonant cavity configurations were presented to support the stable dual-wavelength operation of the laser. Using a polarization beam splitter(PBS) included T-shaped cavity, we obtained a total power output over 5 W in two orthogonal polarized beam directions with 4 W in sigma polarization (1065.5 nm) and 1 W in pi polarization (1063.1 nm). By combining a half-wave-plate with the PBS in the laser cavity, a new configuration favoring one beam direction dual-wavelength output with same polarization direction was realized. A phenomenon of further line splitting was observed in both 1065 nm and 1063 nm.

Expression of angiostatin cDNA in human gallbladder carcinoma cell line GBC-SD and its effect on endothelial proliferation and growth.

AIM: To explore the influence of angiostatin up-regulation on the biologic behavior of gallbladder carcinoma cells in vitro and in vitro, and the potential value of angiostatin gene therapy for gallbladder carcinoma. METHODS: A eukaryotic expression vector of pcDNA3.1(+) containing murine angiostatin was constructed and identified by restriction endonuclease digestion and sequencing. The recombinant vector pcDNA3.1-angiostatin was transfected into human gallbladder carcinoma cell line GBC-SD with Lipofectamine 2000, and paralleled with the vector and mock control. The resistant clone was screened by G418 filtration. Angiostatin transcription and protein expression were examined by RT-PCR, immunofluorescence and Western-blot. The supernatant was collected to treat endothelial cells. Cell proliferation and growth in vitro were observed under microscope. RESULTS: Murine angiostatin cDNA was successfully cloned into the eukaryotic expression vector pcDNA3.1 (+). After 14 d of transfection and selection with G418, macroscopic resistant cell cloning was formed in the experimental group transfected with pcDNA 3.1(+)-angiostatin and vector control. But untreated cells died in the mock control. Angiostatin was detected by RT-PCR and protein expression was detected in the experimental group by immunofluorescence and Western-blot. Cell proliferation and growth in vitro in the three groups were observed respectively under microscope. No significant difference was observed in the growth speed of GBC-SD cells between groups that were transfected with and without angiostatin. After treatment with supernatant, significant differences were observed in endothelial cell (ECV-304) growth in vitro. The cell proliferation and growth were inhibited. CONCLUSION: Angiostatin does not directly inhibit human gallbladder carcinoma cell proliferation and growth in vitro, but the secretion of angiostatin inhabits endothelial cell proliferation and growth.

Angiostatin inhibits pancreatic cancer cell proliferation and growth in nude mice.

AIM: To observe the biologic behavior of pancreatic cancer cells in vitro and in vivo, and to explore the potential value of angiostatin gene therapy for pancreatic cancer. METHODS: The recombinant vector pcDNA3.1(+)-angiostatin was transfected into human pancreatic cancer cells PC-3 with Lipofectamine 2000, and paralleled with the vector and mock control. Angiostatin transcription and protein expression were determined by immunofluorescence and Western blot. The stable cell line was selected by G418. The supernatant was collected to treat endothelial cells. Cell proliferation and growth in vitro were observed under microscope. Cell growth curves were plotted. The troms-fected or untroms-fected cells overexpressing angiostatin vector were implanted subcutaneously into nude mice. The size of tumors was measured, and microvessel density count (MVD) in tumor tissues was assessed by immunohistochemistry with primary anti-CD34 antibody. RESULTS: After transfected into PC-3 with Lipofectamine 2000 and selected by G418, macroscopic resistant cell clones were formed in the experimental group transfected with pcDNA 3.1(+)-angiostatin and vector control. But untreated cells died in the mock control. Angiostatin protein expression was detected in the experimental group by immunofluorescence and Western-blot. Cell proliferation and growth in vitro in the three groups were observed respectively under microscope. After treatment with supernatant, significant differences were observed in endothelial cell (ECV-304) growth in vitro. The cell proliferation and growth were inhibited. In nude mice model, markedly inhibited tumorigenesis and slowed tumor expansion were observed in the experimental group as compared to controls, which was parallel to the decreased microvessel density in and around tumor tissue. CONCLUSION: Angiostatin does not directly inhibit human pancreatic cancer cell proliferation and growth in vitro, but it inhibits endothelial cell growth in vitro. It exerts the anti-tumor functions through antiangiogenesis in a paracrine way in vivo.

Expression of proliferating cell nuclear antigen and CD44 variant exon 6 in primary tumors and corresponding lymph node metastases of colorectal carcinoma with Dukes' stage C or D.

AIM: To study changes in characteristics of colorectal carcinoma during the metastatic process and to investigate the correlation between cell proliferation activity and metastatic ability of patients with Dukes' stage C or D. METHODS: Formalin fixed and paraffin embedded materials of primary tumors and corresponding lymph node metastases resected from 56 patients with Dukes' stage C or D of colorectal carcinoma were stained immunohistochemically with proliferating cell nuclear antigen (PCNA) and CD44 variant exon 6 (CD44v6). RESULTS: Thirty-one of 56 patients (55.4 %) expressed PCNA in the primary sites and 36 of 56 patients (64.3 %) expressed PCNA in the metastatic lymph nodes. A significant relation in PCNA expression was observed between the primary site and the metastatic lymph node (0.010